Armored, Immune Evasive IPS Cell therapies

Our Katana platform transforms iPSCs into cell therapies with plug-and-play antigen specificity, engineered to evade the immune system, find their target, and attack.
Katana platform showing Genetic Editing techniquesKatana platform showing Genetic Editing techniques

iPSC-derived

Why

Current cell therapies rely on patient-derived (autologous) or donor-derived (allogeneic) methods, introducing variability and manufacturing complexity, and limiting re-dosing and accessibility.

How

Our single clone selected iPSCs provide a limitless, single-donor derived, consistently reproducible and renewable source of starting material - a universal solution for scalable cell therapies.
Dashboard mockup

Immune evasive

Why

Current methods to overcome immune rejection can lead to severe side effects, prevent redosing of cell therapies and limit their effectiveness.

How

The Katana platform produces therapeutic cells that evade detection by T-cells, innate immune cells and antibodies, rendering them amenable to redosing.
Dashboard mockup

Armored

Why

Hostile microenvironments limit the ability of therapeutic cells to survive, proliferate, and eliminate diseased cells.

How

Katana cells are armored for enhanced proliferation and potency, increasing their viability and effectiveness.
Dashboard mockup

With this technology, Shinobi enables...

Broader accessibility

Shinobi's immune evasive iPS cell therapies facilitate scalable manufacturing and global distribution.

Solid tumor treatment

Shinobi’s immune evasive iPS cell therapies address tumor heterogeneity and enable redosing for greater efficacy.

Therapies beyond cancer

Shinobi’s therapies have the potential to treat a wide range of intractable diseases, including autoimmune disorders & diabetes.

Pipeline

“I appreciate Shinobi's mission to deliver hypoimmune iPSC-derived NK and T cells to a broad range of patients.”

Dr. Georg Schett, M.D.
Pioneer in CAR-T cell therapy for autoimmune disease and member of Shinobi's Scientific Advisory Board.

Join us in pioneering the next frontier of cell therapy

LinkedIn